Reduced bone mineral density in men following chemotherapy for Hodgkin's disease.

2.50
Hdl Handle:
http://hdl.handle.net/10541/97236
Title:
Reduced bone mineral density in men following chemotherapy for Hodgkin's disease.
Authors:
Holmes, Sarah J; Whitehouse, R W; Clark, S T; Crowther, Derek; Adams, J E; Shalet, Stephen M
Abstract:
We have measured bone mineral density (BMD) in 29 men, mean age 35.0 (range 19.7-58.0) years, with testicular damage following MVPP or hybrid chemotherapy for Hodgkin's disease. Forearm cortical bone mineral content (BMC) and lumbar spine and femoral neck integral BMD were measured 3.4 (1.1-6.8) years after completion of chemotherapy, and results expressed as Z (standard deviation) scores. There was a significant reduction in forearm cortical BMC (median BMC 1.727 g cm-1, median Z-score -0.8, P < 0.0005), in lumbar spine integral BMD (median BMD 1.141 g cm-2, median Z-score -0.6, P < 0.0005) and in femoral neck integral BMD (median BMD 0.991 g cm-2, median Z-score -0.4, P < 0.05). There was no significant correlation between Z-score and time elapsed since completion of chemotherapy, and no significant difference in Z-score according to type of chemotherapeutic regimen or number of cycles of chemotherapy received. In conclusion, men who are in complete remission following treatment of Hodgkin's disease have reduced cortical and trabecular BMD. Possible causes include mild hypogonadism secondary to chemotherapy-induced impairment of Leydig cell function, a direct effect of chemotherapy on bone, an effect of high-dose glucocorticoid on bone or an effect of Hodgkin's disease per se.
Affiliation:
Department of Endocrinology, Christie Hospital NHS Trust, Manchester, UK.
Citation:
Reduced bone mineral density in men following chemotherapy for Hodgkin's disease. 1994, 70 (2):371-5 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Aug-1994
URI:
http://hdl.handle.net/10541/97236
PubMed ID:
8054287
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHolmes, Sarah Jen
dc.contributor.authorWhitehouse, R Wen
dc.contributor.authorClark, S Ten
dc.contributor.authorCrowther, Dereken
dc.contributor.authorAdams, J Een
dc.contributor.authorShalet, Stephen Men
dc.date.accessioned2010-04-23T09:53:25Z-
dc.date.available2010-04-23T09:53:25Z-
dc.date.issued1994-08-
dc.identifier.citationReduced bone mineral density in men following chemotherapy for Hodgkin's disease. 1994, 70 (2):371-5 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid8054287-
dc.identifier.urihttp://hdl.handle.net/10541/97236-
dc.description.abstractWe have measured bone mineral density (BMD) in 29 men, mean age 35.0 (range 19.7-58.0) years, with testicular damage following MVPP or hybrid chemotherapy for Hodgkin's disease. Forearm cortical bone mineral content (BMC) and lumbar spine and femoral neck integral BMD were measured 3.4 (1.1-6.8) years after completion of chemotherapy, and results expressed as Z (standard deviation) scores. There was a significant reduction in forearm cortical BMC (median BMC 1.727 g cm-1, median Z-score -0.8, P < 0.0005), in lumbar spine integral BMD (median BMD 1.141 g cm-2, median Z-score -0.6, P < 0.0005) and in femoral neck integral BMD (median BMD 0.991 g cm-2, median Z-score -0.4, P < 0.05). There was no significant correlation between Z-score and time elapsed since completion of chemotherapy, and no significant difference in Z-score according to type of chemotherapeutic regimen or number of cycles of chemotherapy received. In conclusion, men who are in complete remission following treatment of Hodgkin's disease have reduced cortical and trabecular BMD. Possible causes include mild hypogonadism secondary to chemotherapy-induced impairment of Leydig cell function, a direct effect of chemotherapy on bone, an effect of high-dose glucocorticoid on bone or an effect of Hodgkin's disease per se.en
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBone Density-
dc.subject.meshEtoposide-
dc.subject.meshFollicle Stimulating Hormone-
dc.subject.meshHodgkin Disease-
dc.subject.meshHumans-
dc.subject.meshLuteinizing Hormone-
dc.subject.meshMale-
dc.subject.meshMechlorethamine-
dc.subject.meshMiddle Aged-
dc.subject.meshPrednisolone-
dc.subject.meshProcarbazine-
dc.subject.meshSex Hormone-Binding Globulin-
dc.subject.meshTestosterone-
dc.subject.meshVinblastine-
dc.titleReduced bone mineral density in men following chemotherapy for Hodgkin's disease.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.